An Open-label Longitudinal Study on the Efficacy of Switching from Insulin Glargine or Detemir to Degludec in Type 2 Diabetes Mellitus
| Autor: | Nobuaki Kiyohara, Ken-ichiro Tanaka, Ippei Kanazawa, Toshitsugu Sugimoto, Yuko Tada, Masakazu Notsu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Insulin degludec
Blood Glucose Male Longitudinal study medicine.medical_specialty medicine.medical_treatment Insulin Glargine Type 2 diabetes Drug Administration Schedule Japan Diabetes mellitus Internal medicine Surveys and Questionnaires Internal Medicine medicine Humans Hypoglycemic Agents Insulin Longitudinal Studies Aged Glycated Hemoglobin Insulin glargine business.industry Type 2 Diabetes Mellitus General Medicine medicine.disease Insulin Long-Acting Endocrinology Treatment Outcome Diabetes Mellitus Type 2 Female Open label business medicine.drug |
| Zdroj: | Internal medicine (Tokyo, Japan). 54(13) |
| ISSN: | 1349-7235 |
| Popis: | OBJECTIVE Insulin degludec (IDeg), a new long-acting basal insulin, and FlexTouch, a new injection device, recently became available in Japan. The efficacy and usefulness of IDeg and FlexTouch, compared with insulin glargine or detemir, were assessed in patients with type 2 diabetes mellitus. METHODS We performed an open-label longitudinal trial in 20 patients. After informed consent was obtained, all subjects recorded their self-monitoring data of the blood glucose (BG) level; thereafter, basal insulin was replaced by an IDeg-prefilled FlexTouch with the same dose and duration of time (2 weeks). After using FlexTouch, the patients were provided a device-specific questionnaire. RESULTS The patients were divided into two groups according to the dose of basal insulin (≥10 U and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|